Table 2 Serious adverse events (SAEs) reported as suspected drug of Rifampin or Isoniazid.
Adverse event-no.(%) | Rifampin | Isoniazid | ||||
|---|---|---|---|---|---|---|
Active TB (N = 3560) | Latent TB (N = 262) | Others (N = 1239) | Active TB (N = 51) | Latent TB (N = 2) | Others (N = 18) | |
Death | 2(0.06) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) |
Life-threatening events | 2(0.06) | 2(0.76) | 1(0.08) | 0(0) | 0(0) | 0(0) |
Hospitalization | 99(2.78) | 11(4.20) | 43(3.47) | 1(1.96) | 0(0) | 1(5.56) |
Serious disability or permanent damage | 7(0.20) | 0(0) | 4(0.32) | 0(0) | 0(0) | 1(5.56) |
Congenital anomaly or birth defect | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) |
Others | 40(1.12) | 6(2.29) | 38(3.07) | 8(15.69) | 0(0) | 0(0) |
Total events | 150(4.21) | 19(7.25) | 86(6.94) | 9(17.65) | 0(0) | 2(11.11) |
